New therapeutic could defend against SARS-CoV-2 and future viruses

Written by Tristan Free (Digital Editor)

SARS-CoV-2 therapeutic

Data from preclinical studies of a newly developed antibody shows it to be more effective than monoclonal antibodies in clinical trials, while providing defense against a broader range of threats. As new ground is being broken in vaccine development and the prospects for several successful vaccines against SARS-CoV-2 look promising, the importance of finding a successful treatment for this coronavirus and those like it does not diminish. New in vivo and in vitro data from a novel therapeutic for SARS-CoV-2, currently in preclinical trials, have been released. The data show the therapeutic, an antibody labeled ADG2, to be as (or...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!